State the posture before the timeline. Vertex is, by a wide margin, the largest assignee in the CFTR-modulator patent record, and its protection is not one patent but a stack laid down over more than a decade. The early layer includes US8513282B2, "Modulators of cystic fibrosis transmembrane conductance regulator" (issued August 20, 2013) — a composition-class grant on CFTR-modulating compounds. The recent layer includes US12186306B2, "Methods of treatment for cystic fibrosis" (issued January 7, 2025; CPC A61K 31/4375) — a method-of-treatment grant on how the drugs are used.
The distinction drives the expiry math. Composition-of-matter claims, like the 2013 modulator grant, typically have the earliest priority and are the first to lapse; they are also the hardest to design around while live. Method-of-treatment and formulation claims, filed later, carry later priority dates and can keep protecting a specific dosing regimen or combination after the core compound claims expire. Account for that layering before calling any single expiry date "the" cliff — the franchise cliff is a staircase, not a step.
Be precise about what later grants do and do not extend. A method-of-treatment grant issued in 2025 does not revive an expired composition claim; it protects the specific claimed method. So a generic that practices an unclaimed regimen with an off-patent compound may avoid the later method claims even while the composition is open. The exclusivity question is therefore claim-by-claim and regimen-by-regimen, not franchise-wide.
There is also a modality-shift signal in the record. Translate Bio's US12195505B2, "Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR" (issued January 14, 2025; CPC C07K 14/4702), claims an entirely different approach — delivering mRNA that encodes CFTR rather than a small-molecule modulator. That is a different IP lane targeting the same disease, and it matters for exclusivity because it represents potential competition that does not infringe Vertex's small-molecule claims at all.
For an exclusivity analysis, the discipline is to account for patent-term adjustments and any pediatric exclusivity before drawing the timeline, then to map each claim type to its own expiry. The early composition grants set the floor; the method and formulation grants extend the ceiling on specific uses; and adjacent-modality patents (like nebulized-mRNA CFTR) define competition that sits outside the small-molecule estate entirely.
The reporter's bottom line: Vertex's CF exclusivity is a function of layering. No single grant — not the 2013 composition claim, not the 2025 method claim — tells the whole story. The staircase of priority dates and claim types is the structure, and a credible cliff analysis walks each step, accounts for term extensions, and notes that a different modality could compete without ever touching the modulator claims.